This wasn't funded by MVP.
In fact, (interestingly) I believe most of the studies I post here aren't.
Funding Internal funding was used to conduct this study. SPC receives funding from the US Department of Defense (MIRROR, HU0001-15-2-0003; Congressionally Directed Medical Research Program, 105637007) and National Institutes of Health (GR101558, R01DA048206-01, U24NS115708, 1UH3135804).
Competing interests SPC is a consultant for Avanos, SPR Therapeutics, Persica, and SWORD, and has previously served as a consultant for Clearing and Scilex in the past 3 years. Currently, SPC is the editorial board member of RAPM. SS, PK, WI, NT, SL, RS, and KP have no conflicts of interest to declare.
This wasn't funded by MVP. In fact, (interestingly) I believe...
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.005(1.14%) |
Mkt cap ! $50.13M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.5¢ | 42.0¢ | $74.04K | 171.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40558 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 1342 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MVP (ASX) Chart |